Barclays’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-69,772
Closed -$29K 7655
2018
Q4
$29K Buy
69,772
+69,714
+120,197% +$43.3K ﹤0.01% 5747
2018
Q3
$0 Hold
58
﹤0.01% 7690
2018
Q2
$0 Sell
58
-3
-5% -$7 ﹤0.01% 7625
2018
Q1
$0 Buy
61
+3
+5% +$8 ﹤0.01% 7644
2017
Q4
$0 Hold
58
﹤0.01% 7367
2017
Q3
$0 Hold
58
﹤0.01% 7313
2017
Q2
$0 Hold
58
﹤0.01% 7263
2017
Q1
$0 Hold
58
﹤0.01% 7250
2016
Q4
$0 Hold
58
﹤0.01% 7099
2016
Q3
$0 Sell
58
-486
-89% -$3K ﹤0.01% 6996
2016
Q2
$2K Buy
544
+36
+7% +$235 ﹤0.01% 6037
2016
Q1
$6K Buy
508
+450
+776% +$8.94K ﹤0.01% 5649
2015
Q4
$1K Sell
58
-2,195
-97% -$66.4K ﹤0.01% 5909
2015
Q3
$68K Buy
2,253
+1,225
+119% +$58.6K ﹤0.01% 4847
2015
Q2
$51K Buy
1,028
+889
+640% +$62.7K ﹤0.01% 5130
2015
Q1
$14K Sell
139
-892
-87% -$85K ﹤0.01% 6065
2014
Q4
$92K Buy
1,031
+217
+27% +$20.7K ﹤0.01% 5278
2014
Q3
$56K Buy
814
+752
+1,213% +$59.2K ﹤0.01% 5796
2014
Q2
$5K Sell
62
-6
-9% -$368 ﹤0.01% 7151
2014
Q1
$3K Buy
68
+29
+74% +$957 ﹤0.01% 7368
2013
Q4
$1K Buy
39
+21
+117% +$500 ﹤0.01% 7484
2013
Q3
$0 Sell
18
-5
-22% -$161 ﹤0.01% 7782
2013
Q2
$1K Buy
+23
New +$862 ﹤0.01% 7631

Barclays's PTX Position: Q1 2019 in Review

Barclays sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 69,772 shares — an estimated $29K sold.

Barclays first reported a position in PTX in Q2 2013 and held it in 23 quarters. The position peaked at $92K in Q4 2014. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.

  • Barclays reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
  • Barclays sold 69,772 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $29K.
  • Barclays first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 23 quarters.
  • Barclays's Pernix Therapeutics Holdings, Inc. position peaked at $92K in Q4 2014.
  • 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.

Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.